Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-1898 in Locally Advanced or Metastatic RAIR-DTC
NCT06359847Phase 2Recruiting
- Sponsor
- Beijing Scitech-MQ Pharmaceuticals Limited
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ACC-1898 in differentiated thyroid carcinoma (DTC), sponsored by Beijing Scitech-MQ Pharmaceuticals Limited. Primary endpoint: Objective Response Rate up to 24 months. Started Nov 2023; status: recruiting.
02
Drugs
ACC-1898
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT06359847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06359847.